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In this study, we performed two-dimensional electrophoresis (2-DE) and matrix-assisted laser desorption/ionisation time of fly mass
spectrometry to identify the protein(s) associated with the development of oral squamous cell carcinomas (OSCCs) by comparing
patterns of OSCC-derived cell lines with normal oral keratinocytes (NOKs), and found that downregulation of ubiquitous
mitochondrial creatine kinase (CKMT1) could be a good candidate. Decreased levels of CKMT1 mRNA and protein were detected in
all OSCC-derived cell lines examined (n¼9) when compared to those in primary normal oral keratinocytes. Although no sequence
variation in the coding region of the CKMT1 gene with the exception of a nonsense mutation in exon 8 was identified in these cell
lines, we found a frequent hypermethylation in the CpG island region. CKMT1 expression was restored by experimental
demethylation. In addition, when we transfected CKMT1 into the cell lines, they showed an apoptotic phenotype but no invasiveness.
In clinical samples, high frequencies of CKMT1 downregulation were detected by immunohistochemistry (19 of 52 (37%)) and
quantitative real-time RT–PCR (21 of 50 (42%)). Furthermore, the CKMT1 expression status was significantly correlated with
tumour differentiation (Po0.0001). These results suggest that the CKMT1 gene is frequently inactivated during oral carcinogenesis
and that an epigenetic mechanism may regulate loss of expression, which may lead to block apoptosis.
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Oral cancer is a challenging clinical problem and a leading cause of
cancer deaths for both men and women, with an estimated 300000
new cases annually worldwide (Greenlee et al, 2000). Many risk
factors have already been identified, including human papilloma
virus infection, tobacco use, and alcohol consumption. However,
some patients develop oral squamous cell carcinoma (OSCC)
without risk factors, suggesting that host susceptibility may play a
role. Molecular alterations in a number of oncogenes and tumour-
suppressor genes associated with the development of OSCC could
be important clues to preventing this disease.
Gene expression profiles using cDNA microarrays have been
used to derive a useful molecular-based classification for the
diagnosis, treatment, and prevention of several cancers (Alizadeh
et al, 2000; Bittner et al, 2000). However, biologic systems
comprise protein components resulting from transcriptional and
post-transcriptional control, post-translational modifications,
and protein shifts among different cellular compartments. These
properties cannot be analysed by microarray systems at the RNA
level, whereas proteomic analysis allows separation and visualisa-
tion of the protein content of a cellular sample (Celis et al, 1996).
Considering this, proteome analysis may be a more powerful
analytic technology to enhance study of the diagnosis, treatment,
and prevention of human diseases, including human cancers
(Sanchez et al, 1997; Wolfsberg et al, 2002).
Two-dimensional electrophoresis (2-DE) is the principal tool in
proteomics, which can analyse thousands of proteins in one
experiment, providing the highest resolution in protein separation.
By comprehensively examining the protein expression profiles in
normal and diseased samples via 2-DE, proteomics provides
information on new biomarkers, disease-associated targets, and
pathogenesis (Alaiya et al, 2000; Chambers et al, 2000; Miklos and
Maleszka, 2001). This technique has been used extensively to
investigate various diseases, including SCC of the oesophagus
(Zhang et al, 2003), bladder (Ostergaard et al, 1997; Celis et al,
1999, 2000), lung (Li et al, 2003a,b, 2004), and head and neck (Wu
et al, 2002; Drake et al, 2005; Roesch Ely et al, 2005). However,
little is known about the state of protein expression profiles in
OSCCs. The aim of the present study was to identify the protein(s)
associated with the development of OSCCs by comparing the
patterns of OSCC-derived cell lines with normal oral keratinocytes
(NOKs) using 2-DE and matrix-assisted laser desorption/ionisa-
tion time of fly mass spectrometry (MALDI-TOF-mass). We also
examined the genetic and epigenetic changes and performed
functional analysis of the candidate gene product identified.
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Cells
The nine human OSCCs-derived cell lines used in this study were
Ca9-22, Ho-1-N-1, HSC-2, HSC-3, HSC-4, SAS (Human Science
Research Resources Bank, Osaka, Japan), OK92 (established from
carcinoma of the tongue in our department), Sa3, and H1
(provided by Dr Shigeyuki Fujita, Wakayama Medical University,
Wakayama, Japan). All cell lines were maintained at 371C
(humidified atmosphere 5% CO2/95% air) on 150 20-mm tissue
culture dishes (Nunc, Roskilde, Denmark) and cultured in
Dulbecco’s modified Eagle’s medium F-12 HAM (Sigma Chemical
Co, St Louis, MO, USA) with 10% fetal bovine serum (Sigma) and
50Uml
 1 penicillin and streptomycin. Primary cultured NOKs
were used as a normal control as described previously (Kang et al,
2000; Endo et al, 2004).
Tissue samples and nucleic acid isolation
Tumours with patient-matched normal oral tissues (when avail-
able) were obtained at the time of surgical resection at Chiba
University Hospital after informed consent had been obtained
from the patients according to a protocol that was approved by the
institutional review board of Chiba University. Resected tissues
were divided into two parts: one was frozen immediately and
stored at  801C until use, and the other was fixed in 10% buffered
formaldehyde solution for pathologic diagnosis. Histopathologic
diagnosis of each cancerous tissue was performed according to the
International Histological Classification of Tumours (Wahi, 1971)
by the Department of Pathology, Chiba University Hospital.
Clinicopathologic staging was determined by the TNM Classifica-
tion of the International Union against Cancer (Hermanek et al,
1987). All patients had OSCC that was histologically confirmed,
and tumour samples were checked to ensure the presence of
tumour tissue in more than 80% of specimens. Genomic DNA was
extracted as described previously (Uzawa et al, 1994); total RNA
was prepared using Trizol Reagent (Invitrogen Corp., Carlsbad,
CA, USA), according to the manufacturer’s protocol.
Two-dimensional polyacrylamide gel electrophoresis
The protein expression profiles of seven OSCCs-derived cell lines
(Ca9-22, OK-92, Ho1-N-1, HSC4, SAS, Sa3, and H1) and four NOKs
were examined (Figure 2A). When the cultured cells grew into a
full monolayer, they were washed three times with cold PBS
(Sigma) and treated with lysis buffer containing 30mM Tris-HCl
(pH 7.5), 150mM NaCl, 1% Triton X-100, 10% glycerol, and
protease inhibitor cocktail to generate protein lysates for 10min
at 41C. The cells were collected with a scraper and centrifuged
at 15000r.p.m. for 10min at 41C. Protein concentrations were
determined by the Bradford method. Total protein concentrations
were normalised to 1mgml
 1 for all samples, and the sample
aliquots were stored at  201C until use.
For 2-D polyacrylamide gel electrophoresis (PAGE), each
protein samples (100mg) was mixed with sample buffer containing
7 M urea, 2 M thiourea, 4% (wv
 1) 3-((3-cholamidopropyl)
dimethylammonio)-1-propanesulphonic acid (CHAPS), and 1%
(wv
 1) DTT. Isoelectric focusing for the first dimension of protein
separation was performed with a Multiphore II electrophoresis
system (Amersham Biosciences, Piscataway, NJ, USA). Immobiline
Dry IPG strips (7cm, pH 3–10 nonlinear IPG strips; Amersham
Biosciences) were rehydrated overnight with the sample/rehydra-
tion buffer mixture. The strips were subjected to electrophoresis
using a ramping IPG strip (200–5000V) focusing algorithm. After
isoelectric focusing, the gel strips were equilibrated with sodium
dodecyl sulohate (SDS) equilibration buffer and electrophoresed in
vertical SDS–PAGE slab gels containing 12.5% acrylamide. The
gels of the microdissected samples were fixed and silver stained
using a Silver Quest silver staining kit (Invitrogen Japan, K.K.,
Tokyo, Japan), according to the manufacturer’s instructions.
Two-dimensional gel analysis and MALDI-TOF-mass
spectrometry
The silver stained gel was scanned into Adobe Photoshop 4.0J.
(Adobe, San, Jose, CA, USA) with a Umax Powerlook II scanner
(Umax, Dallas) and printed. Differences in protein levels were
defined as clear visual differences in size, density, or both of the
protein spot on the gel. Phoretix 2D Advanced software (Version
5.01, Nonlinear Dynamic, Ltd., Newcastle, UK) was used to
estimate the relative differences in spot intensity of a candidate
protein. Spots that were consistently and substantially different
were selected for MALDI-TOF-mass analysis (Figure 2A). The
protein spots were excised from the gels, and in-gel digestion was
performed with an enzyme solution containing 50mM NH4HCO3,
5m M CaCl2, and 12.5ngml
 1 trypsin. Aliquots of the purified
samples were spotted on matrix crystals of a-cyano-4-hydroxyl-
cinnamic acid on a stainless steel target and air dried. Mass
determinations were performed on the AXIMA-CFR mass spectro-
meter (Shimadzu Co. Ltd, Kyoto, Japan). The proteins were
identified by the peptide-mass fingerprinting method using Mascot
Search on the Web (Matrix Science, Ltd, London, UK).
Immunofluorescence
Cells were grown on glass coverslips, fixed with methanol for
5min, and permeabilised in 0.01%. Triton X-100 in PBS (pH 7.4)
for 10min. Nonspecific binding was blocked with 5% skim milk in
PBS (pH 7.4) for 1h. Cells were further incubated for 2h with goat
anti-CKMT1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at a
dilution of 1:100, washed with PBS, and incubated with rabbit
anti-goat secondary antibody labelled with Alexa Fluor 488 (Molecular
Probes, Leiden, the Netherlands) for 1h. Further, a DAPI
nuclear stain with (4,6-diamidino-2-phenylindole dihydrochloride)
was performed (0.5mgml
 1). Coverslips were examined by fluores-
cence microscopy (Figure 2A). The microscope used was a Leica
DMIRBE inverted stand equipped with a Leica TCS2-MP confocal
system (Leica Laserteknik, Mannheim, Germany) and Coherent
Mira tunable pulsed titanium sapphire laser (Coherent Laser
Group, Santa Clara, CA, USA).
Immunohistochemistry
Immunohistochemistry (IHC) staining was performed on 4-mm
paraffin-embedded specimens (Figure 2A). Briefly, after depar-
affinisation and hydration, slides were treated with endogenous
peroxidase in 0.3% H2O2 for 30min and the sections blocked for
2h at room temperature with 1.5% blocking serum (Santa Cruz
Biotechnology) in PBS before reacting with anti-CKMT1 (Santa
Cruz Biotechnology) at a dilution of 1:500. Sections then were
incubated with primary antibody for 30min at room temperature
in a moist chamber. After incubation, the sections were washed
three times in PBS buffer and treated with Envision reagent (Dako,
Kyoto, Japan), followed by colour development in 3,30-diamino-
benzidine tetrahydrochloride (Dako). Finally, slides were lightly
counterstained with haematoxylin and mounted. As a negative
control, duplicate sections were immunostained without exposure
to primary antibodies. To quantitate CKMT1 protein expression, a
scoring method was used in which the mean percentage of positive
tumour cells was determined in at least five random fields at  400
magnification in each section. The intensity of the CKMT1
immunoreaction was scored as follows: 1þ, weak; 2þ, moderate;
and 3þ, intense. The percentage of positive tumour cells and
the staining intensity were multiplied to produce a CKMT1
IHC staining (CKMT1-IHC) score for each case. Cases with a
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tissues) were considered negative. Two independent pathologists
without knowledge of or information pertaining to the patients’
clinical status scored the cases. A statistically significance
difference between the CKMT1-IHC scores and clinicopathologic
features was evaluated by the Mann–Whitney’s U-test. Po0.05
was considered significant.
mRNA expression analysis
The expression levels of CKMT1 mRNA were examined in the
tumours, and paired normal oral tissues from the 50 patients with
OSCC, nine OSCC-derived cell lines, and NOKs were analysed
(Figure 2A). Control reactions were prepared in parallel without
reverse transcriptase. Before cDNA synthesis, residual genomic DNA
was removed from the total RNA by DNase I treatment (DNA-free;
Ambion, Austin, TX, USA). The primer sequences used for analysis
of CKMT1 mRNA expression were 50-CCTGCTAAGCAAAGA
TAGCC-30 (nucleotides 1162–1181), 50-TAATGCTTGGTGTGGAT
GAC-30 (nucleotides 1397–1416). The sequence of specific primers
was checked before use to avoid amplification of genomic DNA or
pseudogenes using the Primer3 program (http://www-genome.
wi.mit.edu/cgibin/primer/primer3_www.cgi). The amplified products
were analysed by 3% agarose gel electrophoresis to ascertain the size
and purity of the products. To confirm the identity of the PCR
products, they were cloned into a pCR 2.1vector (Invitrogen) and
sequenced as described previously (Endo et al, 2004).
Real-time quantitative RT–PCR was performed with a single
method using a LightCycler FastStart DNA Master SYBR Green I
kit (Roche Diagnostics GmbH, Mannheim, Germany). To prepare
the standard curve, 1.5mg of total RNA from normal oral tissue was
reverse transcribed with Superscript reverse transcriptase (Life
Technologies, Grand Island, NY, USA) and oligod (T) primer,
after which serial dilutions were made corresponding to cDNA
transcribed from 300, 30, 3.0, and 0.3ng of total RNA. The PCR
reactions using the LightCycler (Roche Diagnostics) apparatus
were carried out in a final volume of 20m1 of reaction mixture
consisting of 2m1 of FirstStart DNA Master SYBR Green I mix
(Roche), and 3mM MgCl2, 0.2m1 of the primers, according to the
manufacturer’s instructions. The reaction mixture was loaded into
glass capillary tubes and submitted to an initial denaturation at
951C for 10min, followed by 45 rounds of amplification at 951C
(10s) for denaturation, 561C (10s) for annealing, and 721C for
extension, with a temperature slope of 201Cs
 1, performed in the
LightCycler. The transcript amount for the CKMT1 gene was
estimated from the respective standard curves and normalised to
the amount of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) transcript determined in corresponding samples.
Mutational analyses
To screen the sequence variations of the CKMT1 gene, PCR-single-
strand confirmation polymorphism (SSCP) analysis and DNA
sequencing analysis were performed as described previously
(Uzawa et al, 1995; Endo et al, 2004) (Figure 2A). Nine sets of
oligonucleotide primers as summarised in Table 3 were used to
amplify the entire coding region (exons 1–9) of the CKMT1 gene.
Sequences for all annotated exons and adjacent intronic sequences
were extracted from public (http://www.ncbi.nlm.nih.gov/) draft
human genome sequences. Primers for PCR amplification and
sequencing were designed using the Primer 3 program as
described above.
Methylation analyses
To determine if methylation of a CpG island of the CKMT1 gene
contributes to the mRNA expression of CKMT1, DNA samples
obtained from the nine OSCC-derived cell lines were analysed
using a PCR-based methylation assay (Figure 2A). The DNA
samples were precipitated with ethanol, dissolved in distilled
water, and further digested with mCpG-sensitive BstUI (1mgU
 1,
New England Biolabs, Beverly, MA, USA) at 601C for 16h. The
BstUI-digested DNAs then were amplified with specific primers for
the CKMT1 CpG island (forward: 50-CAGTGGGTGTCTTTCC
CAGT-30; reverse: 30-GTTCACTGGCAGCTCGTACA-50). The PCR
reactions were performed in a final volume of 25m1 containing
1m1 of digested DNA, 2.5pmol of each specific primer, 50mM of
dNTPs, 10mM Tris-HCl buffer (pH 8.3), 50mM KCl 1.5mM MgCl2,
and 0.5U of AmpliTaq (Applied Biosystems, Foster City, CA,
USA). The amplified PCR products were separated on 3% agarose
gel and visualised by ethidium bromide after the run. DNA from
the NOKs treated in vitro with Sss I methylase (New England
Biolabs) was used as a positive control for methylated alleles. The
Sss I-untreated DNA was used as a negative control for methylated
genes. To assess reactivation of CKMT1 mRNA expression,
demethylating assay was performed using the DNA methyltrans-
ferase inhibitor, 5-aza-20-deoxycytidine (5-aza-20-dC) (Sigma
Chemical Co.), as described previously (Yamamoto et al, 2001)
(Figure 2A). The cells were treated with different concentrations
(0 and 2mM) of 5-aza-20-dC. On day 5, the cells were washed with
PBS and grown for another 10 days without the demethylating
chemical. The cells then were harvested, and total RNA was
extracted, and the expression of the CKMT1 gene was evaluated by
real-time quantitative RT–PCR as described above.
Transiently transfection
Human CKMT1 cDNA was cloned into a pME18SFL3 expression
vector for transient transfection experiments (Joshi et al, 2002)
(Figure 2A). The nine OSCC-derived cell lines were transfected
with pME18SFL3 encoding CKMT1 cDNA using the nonliposomal
formulation FuGENE-6 transfection reagent (Roche; Tao et al,
2004). All experiments using these cells were performed 48h after
transfection. Mock transfection of the nine OSCC-derived cell lines
cultures with pME18SFL3 expression vector alone was used as a
control. Real-time quantitative RT–PCR analyses and immuno-
fluorescence were performed to confirm transfection efficiency.
In vitro invasion assay
The invasive activity of the nine CKMT1-transfected cells and nine
mock-transfected cells in vitro were tested using a QCM 96-Well
Cell Invasion Assay Kit (Chemicon, Temecula, CA, USA; Wang
et al, 1997; Ciolczyk-Wierzbicka et al, 2004) (Figure 2A). The cells
were loaded into a chamber coated with ECMatrix at a density of
5 10
5 cellsml
 1 in 0.1ml serum-free Dulbecco’s modified Eagle’s
medium F-12 HAM. The plates with cells were incubated for 16h at
371Ci naC O 2 incubator. Migrating cells on the bottom of the
insert were incubated with 150m1 of prewarmed cell detachment
buffer for 30min, dissociated from the membrane, and detected by
CyQuant GR dye. The fluorescence plate was read using a 480/
520nm filter set.
Apoptosis assay
Apoptosis detection was carried out using a terminal deoxy-
nucleotidyl transferase-mediated deoxyuridine triphosphate
(dUTP)-biotin nick end labeling (TUNEL) method (Tornusciolo
et al, 2004) with an In situ Apoptosis Detection Kit (Takara), according
to the manufacturer’s protocol (Figure 2A). Briefly, the cells were
fixed in 4% neutral buffered formalin, dried onto microscope
slides, washed with PBS, equilibrated, and incubated with terminal
deoxynucleotidyl transferase in a reaction buffer containing
digoxigenin dUTP at 371C for 1h. The reaction was stopped, the
specimens were washed for 30min, and the slides were incubated
with anti-digoxigenin antibody coupled to FITC for 30min at room
CKMT1 in oral cancer
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stemperature and washed three times with PBS before mounting for
photomicrography under phase and epifluorescence illumination.
Apoptotic index was determined by calculating the percentage of
cells that was apoptotic through positive staining. All slides were
blindly evaluated by three independent times.
RESULTS
Two-dimensional PAGE
Protein samples were extracted from the OSCC-derived cell lines
and concentrations determined by the Bradford method using
SmartSpec 3000 (Bio-RAD, Hercules, CA, USA). Total protein
extraction rates did not differ significantly between the OSCC-
derived cell lines and NOKs. Usually 100mg of proteins per sample
were used for 2-D PAGE separation. The proteins were distributed
evenly in the 7-cm gel with isoelectric points in the range of 3–10
and molecular masses of 6–200kDa. Figure 1A shows typical
master gel images for OSCC-derived cell lines and NOK samples.
About 450 protein spots in each gel were detected using the
Phoretix Two-Dimensional Advanced v5.01 analysis program.
Proteins with a 42-fold change in expression were considered
significant. Three proteins were upregulated and 27 proteins were
suppressed significantly in OSCC-derived cell lines compared with
NOKs.
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Figure 1 (A) Representative master 2-DE gel images of NOK and OSCC-derived cell line (Ca9-22) samples. After isoelectric focusing for the first
dimension of protein separation, the gel strips were electrophoresed in vertical SDS–PAGE slab gels and stained with silver. Close-ups of 2-DE gel images
were significantly downregulated in the OSCC-derived cell lines compared with the NOKs. Mw, molecular weight. (B) Results of MALDI-TOF-mass
spectrometric analysis of this spot. Amino-acid sequences analysed by peptide mass fingerprinting analysis are redlined on the full-length sequence of the
CKMT1 protein.
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Each protein spot was excised and subjected to in-gel tryptic
digestion, MALDI-TOF-mass measurement, and database match-
ing. We identified five candidate proteins that were differentially
expressed in OSCC cell lines compared with NOKs. Table 1 shows
the proteins identified; most of the matched proteins had high
sequence coverage, mass accuracy, and MOWSE scores. We
identified CKMT1 as a potentially novel molecular marker for
OSCCs using this technique (Figure 1B).
Immunofluorescence
We examined the expression level of the CKMT1 proteins based on
the results of proteomic analyses by immunofluorescence analysis.
Nine OSCCs-derived cell lines and NOKs were examined. The
CKMT1 proteins in the NOKs were surrounded by obvious green
fluorescence; no fluorescence was seen in all OSCC-derived cell
lines. The data were matched to the proteomic study. Figure 2C
shows a representative result of significant decrease expression of
CKMT1 protein in the OSCC-derived cell line, when compared to
its expression in NOK (Figure 2B).
Immunohistochemistry
Among 52 OSCCs analysed by IHC staining, 19 had significantly
decreased expression of CKMT1 (IHC score o62.2). In contrast, all
normal tissues had a strong cytoplasmic immunoreaction for
CKMT1. There was a statistically significant difference between the
frequency of CKMT1-negative cases and clinicopathologic features
(Table 2). All 21 (100%) oral premalignant lesions (OPLs) were
CKMT1-positive. Figure 3A–F shows representative results for
CKMT1 protein expression in normal oral tissue, OPLs, and
primary OSCCs. The CKMT1-IHC scores for normal tissues, OPLs,
OSCCs, well, moderately and poorly differentiated type of OSCCs,
respectively, ranged from 62.2 to 200 (mean, 116.5), 67.5 to 200
(mean, 120), 0 to 200 (mean, 88.5), 0 to 200 (mean, 92.6), 0 to 123.4
(mean, 56.6), and 0 to 29.6 (mean, 12.6). CKMT1 expression levels
in both moderately and poorly differentiated tissues were
significantly lower than those in normal oral tissues (P¼0.0002
and P¼0.0001, respectively). In contrast, we found no significant
difference in the CKMT1 IHC scores among normal oral tissue,
OPLs, and well-differentiated tumours (P¼0.966 and P¼0.945,
respectively) (Figure 3G).
mRNA expression analysis
Real-time quantitative RT–PCR analysis data were matched to the
protein expression values in the 2-DE analyses, immunofluores-
cence analyses, and immunohistochemistry analyses. mRNA
expression of CKMT1 was significantly reduced in tumours of
randomly selected CKMT1-negative cases (n¼21) compared to
the selected CKMT1-positive cases (n¼29). mRNA expression
levels were normalised to GAPDH. The relative mRNA expression
level in the normal tissues and primary OSCCs ranged from 0.1 to
20.1 (mean, 2.02) and 0.02 to 10.6 (mean, 0.86), respectively
(Figure 3H). There was no statistically significant difference
between the frequency of CKMT1-negative cases and clinicopatho-
logic features (Table 2). A significant decrease in CKMT1
expression was observed in OSCC-derived cell lines compared
with NOKs used as controls (Figure 2D). The data are expressed as
the mean7s.d. of three independent experiments with samples in
triplicate.
Mutational analyses
To investigate the mechanisms responsible for downregulation
of CKMT1 gene expression in OSCC-derived cell lines, we analysed
genomic DNA by PCR-SSCP and direct sequence analyses. A band
shift was detected in four of the nine (44%) OSCC-derived cell
lines (Ho-1-N-1, HSC-2, HSC-4, SAS). Sequence variations were
observed in exon 8. All sequencing variations were nonsense
mutations (AAA changed to AAG and lysine changed to lysine) at
codon 407 (data not shown).
Methylation analyses
We analysed the methylation status of the CpG island region of the
CKMT1 gene in the 9 OSCC-derived cell lines. CKMT1 methylation
was detected in four (44%) of the cell lines (Ho-1-N-1, HSC-2,
HSC-3, HSC-4), whereas NOKs had no methylation allele.
Figure 4A shows representative results of methylation status. To
further study the consequences of loss of expression of CKMT1 in
association with CpG island hypermethylation in OSCC-derived
cell lines, the cell lines with methylation and transcriptional
inactivation of CKMT1 were treated with 5-aza-20-dC. Significant
upregulation (in Ho-1-N-1, HSC-2, HSC-3, HSC-4) of mRNA
expression was observed after 5-aza-20-dC treatment (Figure 4B).
The results were matched to methylation states studied in a PCR-
based methylation assay. The data are expressed as the mean7s.d.
of three independent experiments with samples in triplicate.
Functional analysis of CKMT1
To confirm transfection efficiency, quantitative real-time RT–PCR
analyses and immunofluorescence were carried out. Quantitative
real-time RT–PCR showed that CKMT1 was overexpressed 30–
5000-fold in CKMT1-transfected OSCC-derived cell lines compared
with mock-transfected OSCC-derived cell lines and untreated cell
lines (Figure 5A). On immunofluorescence, no significant differ-
ence in the CKMT1 expression pattern was observed between
mock-transfected OSCC-derived cell lines and untreated cell lines.
In contrast, all CKMT1-transfected OSCC-derived cell lines had a
strong immunoreaction for CKMT1.
The invasive activity of the nine CKMT1-transfected cell lines
and the nine mock-transfected cell lines were tested using the
ECMatrix invasion chamber assay. Transfection of OSCC-derived
cell lines with CKMT1 produces no significant decrease in invasive
activity (data not shown).
To assess the specific role of CKMT1 downregulation, we
evaluated the apoptotic ability between CKMT1-transfected OSCC-
derived cell lines and the mock-transfected OSCC-derived cell
Table 1 Results of MALDI-TOF mass spectra and database searching for protein identification
Protein name Peptides matched Sequence coverage Mowse score
a Cancer cells (up or down)
Creatine kinase, mitochondrial 8 20(%) 97 Down
Acetyl-Coenzyme A acyltransferase 9 28(%) 92 Down
Aldolase C, fructose-bisphosphate 9 23(%) 86 Up
Similar to hydroxyacyl-Coenzyme A dehydrogenase 8 37(%) 106 Up
Dystrophin-related protein 3 8 19(%) 70 Up
aMOWSE scores over 67 were significant (Po0.05). MALDI-TOF-mass¼matrix-assisted laser desorption/ionisation time of fly mass spectrometry.
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slines. Cell morphology was analysed using optical microscopy.
Morphological change showing apoptotic bodies, such as decrease
of cellular and nuclear sizes, were observed in all CKMT1-
transfected OSCC-derived cell lines, but not in mock-transfected
OSCC-derived cell lines. TUNEL-positive cells were virtually
undetected in mock-transfected OSCC-derived cell lines, whereas
all the CKMT1-transfected OSCC-derived cell lines had increased
numbers of TUNEL-positive cells (Figure 5B). The apoptotic index
for CKMT1-transfected OSCC-derived cell lines and mock-
transfected OSCC-derived cell lines, respectively, ranged from
26.92 to 76.58 (mean, 43.25), 2.77 to 14.12 (mean, 6.42).
DISCUSSION
We identified CKMT1 as a potentially novel molecular marker
for OSCCs. Creatine kinase (CK), originally found in cytosol and
the mitochondria of cells, catalyses the reversible exchange of
high-energy phosphate between ATP and phosphocreatine (PCr;
Wallimann et al, 1992; Wallimann et al, 1998). Cytosolic CKs are
dimmers consisting of muscle-type subunits, brain-type subunits,
or both. However, two genotypes of mitochondrial CK have been
identified, that is, CKMT1 and the sarcomeric mitochondrial CK
that are encoded by two different genes on human chromosomes
15 and 5 and expressed in a tissue-specific manner (Stallings et al,
1988; Haas et al, 1989). CKMT1 is coexpressed with the cytosolic
brain-type subunits in many cells and tissues with high-energy
demand, such as the brain, placenta, kidney, testis, sperm, or
endothelial cells. The enzyme is thought to have two main
functions in energy metabolism (Wallimann et al, 1992): it buffers
the cellular ATP pool by maintaining high cytosolic concentrations
of PCr, which can be used in times of high cellular energy demand
to regenerate ATP, and it maintains an energy shuttle between
subcellular sites of energy supply (oxidative phosphorylation,
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Figure 2 (A) A diagram of the experimental process. For details, see Materials and Methods. Immunofluorescence analyses show the status of CKMT1
protein expression. The CKMT1 proteins of the NOK (B) are surrounded by green fluorescence; fluorescence is not seen in the OSCC-derived cell line
(OK92) samples (C). (D) Quantification of mRNA levels in OSCC-derived cell lines by real-time RT–PCR analysis. Significant downregulation of the CKMT1
gene is seen in all cell lines compared to CKMT1 mRNA expression in NOKs. Data are expressed as means7s.d.
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sglycolysis) and sites of energy demand using the easily diffusible
creatine (Cr)/PCr. For example, CKMT1, located in the mitochon-
drial intermembrane space, preferentially catalyses the phosphory-
lation of Cr to PCr, which then diffuses into the cytosol where it is
used in a reverse reaction by cytosolic CK to restore ATP for
different, often closely associated ATPases (Schlattner et al, 1998).
In addition, CKMT1 has been implicated in the regulation of the
Ca
2þ-induced mitochondrial permeability transition pore (PTP;
O’Gorman et al, 1997). PTP is involved in triggering apoptosis by
releasing proapoptotic factors into the cytosol (Crompton, 1999).
Several studies have shown the aberrant expression of CKMT1 in
cancers of various organs, including lung cancer, breast cancer,
gastric cancer, colon cancer, and prostate cancer (DeLuca et al,
1981; Tsung, 1983; Kanemitsu et al, 1984; Wallimann et al, 1992),
suggesting that CKMT1 is involved in the pathogenesis of various
cancers. However, there has been no report regarding CKMT1
expression in oral cancer, which lead us to further analyse this
potential protein.
In the present study, we showed the state of CKMT1 gene
mutation and its mRNA/protein expression in OSCC-derived cell
lines and NOKs by SSCP/DNA sequencing, quantitative real-time
RT–PCR, and immunofluorescence. Our data indicate that
CKMT1 expression decreases or is lost in OSCC-derived cell lines
but is abundant in NOKs. When DNA from OSCC-derived cell
lines was analysed, we found nonsense mutations in the coding
sequence of the CKMT1 gene. In contrast to mutational analyses,
quantitative real-time RT–PCR analysis of CKMT1 mRNA showed
frequent downregulation of the gene in all cell lines, indicating
that other mechanisms, such as post-transcriptional modification
and upregulated degradation, may be involved in CKMT1 gene
silencing. In this context, with accumulating knowledge of the
mechanisms of inactivation of tumour-suppressor genes, abnormal
methylation at the promoters of tumour-suppressor genes is
another mechanism that suppresses gene activity (Jones and Laird,
1999). In oral tumours, the promoters of several tumour-
suppressor genes, that is, p16, p15, p14, and E-cadherin, are
highly methylated in addition to a rare gene mutation in human
OSCCs (Saito et al, 1998; Miracca et al, 1999; Shintani et al, 2001).
In the present study, we found an association between methylation
and suppression of CKMT1 gene expression in OSCC-derived cell
lines. Treatment of OSCC-derived cell lines showed that CKMT1
methylation with a demethylating agent restored or significantly
upregulated CKMT1 expression. These findings indicate that
reduced expression of the CKMT1 gene may be linked to human
oral carcinogenesis and/or progression of cancer due to epi-
genetic silencing. Thus, we suggest that CKMT1 could be a class II
Table 2 Correlation between CKMT1expression and classification in oral squamous cell carcinomas
Result of immunostaining: no. of patients (%) Result of real-time PCR: no. of patients (%)
Clinical classification Total CKMT1 ( ) CKMT1 (+) P-value Total CKMT1 ( ) CKMT1 (+) P-value
Age at surgery (year)
p49 12 2(17) 10(83) 6 2(33) 4(67)
50–59 16 9(56) 7(44) 0.208971 13 6(46) 7(54) 0.722219
60–69 12 4(33) 8(67) 13 7(54) 6(46)
70 12 4(33) 8(67) 18 6(33) 12(67)
Gender
Male 31 13(42) 18(48) 32 13(41) 19(59) 1
Female 21 6(29) 15(71) 0.388742 18 8(44) 10(56)
T-primary tumour
T1 4 0(0) 4(100) 5 2(40) 3(60)
T2 26 9(35) 17(65) 0.223836 30 9(30) 21(70) 0.117337
T3 6 4(67) 2(33) 5 3(60) 2(40)
T4 16 6(38) 10(62) 10 7(70) 3(30)
N-regional lymph node
N( ) 38 15(39) 23(61) 0.533534 18 5(28) 13(72) 0.1485
N(+) 14 4(29) 10(71) 32 16(50) 16(50)
Stage
I 4 0(0) 4(100) 2 1(50) 1(50)
II 15 5(33) 10(67) 0.115748 13 3(23) 10(77) 0.213194
III 5 4(80) 1(20) 14 4(29) 9(71)
IV 28 10(36) 18(64) 21 12(57) 9(43)
Histopathologic type
Well differentiated 35 5(14) 30(86) 42 15(36) 27(64)
Modelately differentiated 11 8(73) 3(27) o0.0001 7 5(71) 2(29) 0.0633215
Poorly differentiated 6 6(100) 0(0) 1 1(100) 0(0)
Tumour site
Gingiva 16 5(31) 11(69) 17 7(41) 10(59)
Tongue 26 10(38) 16(62) 19 6(32) 13(68)
Buccal mucosa 4 0(0) 4(100) 0.298623 7 3(43) 4(57) 0.30294
Oral floor 3 2(67) 1(33) 2 1(50) 1(50)
Oropharyngeal isthmus 3 2(67) 1(33) 2 2(100) 0(0)
Lower lip — — — 2 2(100) 0(0)
Soft palate — — — 1 0(0) 1(100)
Leukoplakias 21 0 21 — — — — —
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stumour-suppressor gene in that it is structurally intact in sequence
but underexpressed or unexpressed due to downregulation or
silencing in transcription or translation (Jones and Laird, 1999).
These data show that proteomic analyses coupled with genetic and
epigenetic analyses may be an essential strategy to discover novel
molecular targets in the development of OSCCs.
To confirm the correlation between invasiveness and reduction
of the CKMT1 protein, we examined the invasive activity of
CKMT1-transfected OSCC-derived cell lines and mock-transfected
OSCC-derived cell lines by in vitro invasion assay. The results
showed that transfection of OSCC-derived cell lines with CKMT1
produces no substantial difference in invasive activity. We suggest
that CKMT1 is unrelated to the invasiveness of the cells and
suppresses or promotes metastasis of OSCCs.
To assess the specific role of CKMT1 downregulation, we
evaluated apoptotic ability. The results showed that all
P< 0.0001
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Figure 3 Immunohistochemistry staining of CKMT1 in normal and tumorous oral tissues. (A) Normal oral tissue exhibits CKMT1 protein expression,
which is limited to the cytoplasm of the epithelial cells. (B) CKMT1-positive case of OPL (leukoplakia). (C) CKMT1-positive case of well-differentiated
primary OSCC. (D) CKMT1-negative case of well-differentiated primary OSCC. (E) CKMT1-negative case of moderately differentiated primary OSCC. (F)
CKMT1-negative case of poorly differentiated primary OSCC. Original magnification  200. (G) CKMT1 protein expression levels in moderately
differentiated and poorly differentiated tumours are significantly lower than in normal oral tissues. No significant difference in the CKMT1 IHC scores is seen
among normal oral tissue, OPLs, and well-differentiated tumours. (H) CKMT1 mRNA expression status in primary OSCCs. The relative mRNA expression
level in normal tissues and primary OSCCs ranges from 0.1 to 20.1 (mean, 2.02) and 0.02 to 10.6 (mean, 0.86), respectively. There is a significant difference
in the CKMT1 mRNA expression levels between negative and positive cases (P¼0.0008, Mann–Whitney’s U-test).
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sCKMT1-transfected OSCC-derived cell lines had increased TUNEL-
positive cells compared with mock-transfected OSCC-derived cell
lines. Apoptosis can be mediated via several pathways, one of which
involves the engagement of the so-called death receptors belonging
to the tumour necrosis factor receptor superfamily. A cascade of
proteolytic digestion occurs, involving caspases, resulting in cell
death. However, caspase-8 may digest the Bid protein to yield a
truncated form that can induce mitochondrial damage, eventually
leading to cell death. In addition, many agents induce cellular
stress, which can also lead to mitochondrial perturbation and
ultimately cell death. A mechanism causing the mitochondrial
dysfunction mentioned previously has been proposed that consists
of mitochondrial membrane permeability transition, dissipation
of the inner membrane potential, osmotic swelling of the matrix,
rupture of the outer mitochondrial membrane, release of
cytochrome c and other apoptogenic proteins from the mitochon-
dria, and formation of the caspase-3 activation complex, the
apoptosome (Debatin et al, 2002; Newmeyer and Ferguson-Miller,
2003). Permeability transition involves the opening of a PTP. The
main components of this pore are adenine nucleotide translocator
(ANT) and cyclophilin D in the inner membrane of the
mitochondria and a voltage-dependent anion channel and a
peripheral benzodiazepine receptor (VDAC) in the outer mito-
chondrial membrane. The PTP is formed in regions of contact
between the inner and outer mitochondrial membranes. Prolonged
opening of the PTP leads to the previously mentioned effects,
exposes cytosol to the contents of the mitochondria, and
culminates in cell death (Debatin et al, 2002; Newmeyer and
Ferguson-Miller, 2003). Interestingly, mitochondrial permeability
transition can lead to both apoptosis and necrosis (Lemasters et al,
1998). CKMT1 is located in the intermembrane space and also
interacts with VDAC–ANT complexes (Marzo et al, 1998). We
suggest that CKMT1 might induce apoptosis through specialised
systems such as the PTP in OSCCs.
We showed the status of CKMT1 expression in clinical tissue
samples obtained from primary OSCCs and the corresponding
normal oral mucosa by quantitative real-time RT–PCR and
IHC staining; high frequencies of CKMT1 downregulation were
detected. Moreover, no difference in protein expression was
observed in OPLs. In addition, we found a significant correlation
between CKMT1 expression status and the clinicopathologic
features. Most of the primary OSCCs diagnosed as moderately or
poorly differentiated tumours showed downregulation of CKMT1
protein expression, and a statistically significant difference was
Table 3 Primers and parameters for PCR-single-strand confirmation polymorphism (SSCP) analysis
Gene Forward (50–30) Reverse (30–50) Product size (bp) Number of cycle Annealing condition
CKMT1 (15q15)
Exon1 CCCTGTTCCGGATCTTATCT CCGGATTCTCACTTCTACCC 292 35 641C, 10s
Exon2 CCCTCCATGGTTACTGGGTA TGGATCATCAGGGAGACTCTG 264 35 641C, 10s
Exon3 TTGAAGTCTGGGGAGGGATT ACACAGGCAATGCAAATCAG 196 35 641C, 10s
Exon4 CAATGCATGCAGGAAGAATG CTGCTGTTCAGCCTCTGTCA 332 35 641C, 10s
Exon5 CCAGATGAGACATGGGCTCT TCAAGAGGCAAGGCAAGAAT 254 35 641C, 10s
Exon6 ATTCTTGCCTTGCCTCTTGA ATGTCCTGGGTTGGTTGGTA 267 35 641C, 10s
Exon7 TAAGGGAGGGTCCAGGGTTA CTTTCCAAAGGGTCCACTCC 283 35 641C, 10s
Exon8 CAGGTTCAGGGCTCTTTCAG CTTGCCTGCTCATTTCCAAT 344 35 641C, 10s
Exon9 ATTGGAAATGAGCAGGCAAG AGACAGCTGCAGCATAGCAA 343 35 641C, 10s
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Figure 4 (A) Typical results of the methylation assay. CKMT1 methylation is seen in four OSCC cell lines (Ho-1-N-1, HSC-2, HSC-3, and HSC-4), which
show reduced CKMT1 mRNA expression. DNA from NOK treated in vitro with SssI methylase is used as a positive control (lane PC) for methylated alleles.
SssI-untreated DNA is used as a negative control (lane NC) for methylated genes. M, molecular marker. (B) Quantitative real-time RT–PCR analysis for
demethylation assay in CKMT1-methylated OSCC cell lines. Restoration or upregulation of CKMT1 mRNA expression is detected in all CKMT1-methylated
OSCC cell lines after treatment with the DNA demethylating agent 5-aza-20-dC. þ,2mM 5-aza-20-dC treatment;  ,0mM 5-aza-20-dC treatment.
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sobserved between the CKMT1-reduced primary OSCCs and the
histopathologic type (Po0.0001). Recently, a relation between
mitochondrial homeostasis and tumour differentiation was re-
ported (Krueger, 1995; Morgan et al, 2004). For example, the
VDAC is mainly found on the outer mitochondrial membrane of
cells as described previously. The VDAC plays a role in several
cellular functions including haem synthesis, steroidogenesis, DNA
synthesis, cell growth and differentiation, and apoptosis (Krueger,
1995). In cutaneous neoplasms and other skin diseases, a
heterogeneous pattern of VDAC expression at lower intensity
was seen depending on the tumour type and the degree of
differentiation (Morgan et al, 2004). The VDAC expression was
greatest in well-differentiated tumours, synonymous with the
VDAC expression gradient seen in normal skin, and least in poorly
differentiated and infiltrative tumours (Morgan et al, 2004).
Although we have not examined the relationship between CKMT1
expression and oral cancer cell differentiation in vitro, above-
mentioned evidences and our data suggest that change of
mitochondrial homeostasis, in part, causes tumour differentiation.
Furthermore, the potential role of CKMT1 in the regulation of both
differentiation and apoptosis could be involved in the development
of OSCC.
Based upon our data, we have concluded that downregulation
of CKMT1 is, in part, involved in the oral carcinogenesis and that
an epigenetic mechanism may regulate loss of its expression,
which leads to block apoptosis through specialised systems such as
mitochondrial permeability transition pores in oral cancer cells.
Further investigations with greater number of clinical samples
including precancerous lesions are needed to improve our ability
to diagnose, prevent, and treat this neoplasm.
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